Aardvark Therapeutics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AARD research report →
Companyaardvarktherapeutics.com
Aardvark Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
- CEO
- Tien-Li Lee
- IPO
- 2025
- Employees
- 22
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $92.28M
- P/E
- -1.32
- P/S
- 0.00
- P/B
- 1.06
- EV/EBITDA
- -0.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.71%
- ROIC
- -85.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-57,591,000 · -179.73%
- EPS
- $-2.64 · -177.89%
- Op Income
- $-62,725,000
- FCF YoY
- -198.24%
Performance & Tape
- 52W High
- $17.94
- 52W Low
- $3.35
- 50D MA
- $4.89
- 200D MA
- $10.15
- Beta
- 5.11
- Avg Volume
- 303.06K
Get TickerSpark's AI analysis on AARD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Sun Nelson | other | 70,549 |
| Feb 9, 26 | Jaiman Manasi | other | 70,549 |
| Feb 9, 26 | Lee Tien-Li | other | 203,851 |
| Dec 11, 25 | Sun Nelson | buy | 3,000 |
| Dec 11, 25 | Lee Tien-Li | buy | 7,000 |
| Oct 15, 25 | Lee Tien-Li | other | 1,229 |
| Oct 15, 25 | Lee Tien-Li | other | 1,229 |
| Oct 15, 25 | Jones Bryan | other | 1,250 |
| Oct 15, 25 | Jones Bryan | other | 1,250 |
| Sep 15, 25 | Lee Tien-Li | buy | 3,500 |
Our AARD Coverage
We haven't published any research on AARD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AARD Report →